BTOG retweeted
@ThomasW35874311 The role of surgery in advanced lung cancer. Pushing the boundaries…. All about selecting the right patient. It was intriguing to hear views that would challenge uk practice. @BTOGORG #ESMO26
BTOG retweeted
Out now in the @JTOonline: First study of the Y220C TP53mutation in NSCLC by ETOP IBCSG investigators. Among 28,244 patients, 195 (0.7%) harbored the Y220C, and half of them (100/195) did not carry any known drivers.
jto.org/article/S1556-0864(2…
A 94% response rate in TKI-naïve ROS1-positive lung cancer was one of the standout results discussed at WCLC 2026.
Hear @DrRiyazShah and @tnewsomdavis assess the data and what could come next.
On our website, YouTube or your favourite podcast platform
btog.org/btog-wclc-update-we…
#LCSM #lungcancer
The website is back up and running but we're waiting for a permanent fix from our host, thank you all for your patience!
Our website host had a power outage early this morning and they're just bringing services back up. Apologies for any inconvenience, we'll let you know when the site is available again.
📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 btog.org/25th-btog-annual-co…
#LCSM
BTOG retweeted
At #WCLC26, @sindhubnaidu explores incidence of driver mutations across never smokers with #lungcancer, finding variation amongst patient groups 🚬🚫
Watch: ow.ly/LM5g50ZYsNq
#LCSM #Oncology @IASLC
BTOG retweeted
🫁 With the launch of the new IREX-Lung International Collaborative Network, @pompili_cecilia joined us for an insightful interview on the #WCLC26 workshop held on the initiative and the future of exercise in thoracic oncology
➡️ Watch: buff.ly/YDqlWUE
#lcsm
Want to know what to expect from the BTOG Annual Conference?
Take a look back at some of the highlights from 2026 with our YouTube Shorts playlist – around an hour of sessions, insights and discussion from across thoracic oncology.
Watch here:
youtube.com/playlist?list=PL…
Then discover what’s planned for BTOG 2027:
btog.org/25th-btog-annual-co…
#BTOG2027 #ThoracicOncology #LungCancer
The latest BTOG Trainee eNews is out now.
Research, trainee-led projects, education and opportunities for trainees working in thoracic oncology.
Read the October edition and sign up to receive future issues:
btog.org/trainee-enews-octob…
BTOG retweeted
🚨 New insights from DeLLphi-309: Tarlatamab extended-interval dosing demonstrates comparable efficacy in patients with SCLC.
🔗 Read the recap from #WCLC26 in ILCN: bit.ly/4AZ9EZD
#LCSM
BTOG retweeted
Great synopsis of DLL3 Targeting at @btog SCLC study day by Dr Sean Dulloo @uniofleicester @Leic_hospital
Where does thoracic radiotherapy fit in extensive-stage #SCLC in the immunotherapy era?
Dr Huiqi Yang: consolidation RT should be offered to good responders after chemotherapy, but its role following chemoimmunotherapy remains uncertain.
#BTOGSCLC26 #LCSM
Could radiopharmaceuticals become another way to target #SCLC?
Dr Toby Talbot explains how a radioisotope can be delivered to tumour-specific targets – a similar principle to an ADC, but with radiation replacing the drug payload.
#BTOGSCLC26 #LCSM
BTOG retweeted
@DrRiyazShah: is long-term in SCLC achievable?
Answer: ✅
Have we achieved it yet? ❌
LS-SCLC:
3yr OS = ~56%
?long-term survival with longer follow up
ES-SCLC:
Up to 22% 4yr survival (ASTRUM)
11% 7yr survival (Imbrella-A)
🔺Can’t predict at start of treatment who will be long-term survivor
❓Will T-cell engagers give even longer survival
BTOG retweeted
Tom Combellack: What is resectable in SCLC?
🔸 Uncommon, but important to remember
❌ Sub-lobar resection not recommended
✅ Adjuvant chemotherapy is recommended
✅ CRT if R1/R2 and/or N2 disease
❓PCI question very pertinent given MAVERICK data & ongoing PRIMALUNG
Caveats:
⚠️ Retrospective data, with selection bias
